18 unchanged sentences
(the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria.
−Removed: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive loss, convertible preferred stock and stockholders’ equity (deficit) and cash flows for each of the three years in the period ended December 31, 2019, and the related notes and our report dated February 27, 2020 expressed an unqualified opinion thereon.
+Added: We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2020 and 2019, the related consolidated statements of operations and comprehensive income (loss), stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2020, and the related notes and our report dated February 26, 2021 expressed an unqualified opinion thereon.
Basis for Opinion
82 unchanged sentences
10-K 001-38311 10.12.1 3/19/2018
−Removed: 10.13+ Key Executive Change in Control and Severance Plan.
−Removed: S-1 333-221522 10.13 11/13/2017
+Added: 10.12.2# Amendment No.
+Added: 3 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No.
+Added: 1 on October 18, 2017 and Amendment No.
+Added: 2 dated January 18, 2018, dated July 2, 2018 .
+Added: 10-Q 001-38311 10.1 11/8/2018
+Added: 10.12.3# Amendment No.
+Added: 4 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No.
+Added: 1 on October 18, 2017 and Amendment No.
+Added: 2 dated January 18, 2018, and Amendment No.
+Added: 3 dated July 2, 2018, dated August 30, 2018 .
+Added: 10-Q 001-38311 10.2 11/8/2018
+Added: 10.12.4# Amendment No.
+Added: 5 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No.
+Added: 1 on October 18, 2017, Amendment No.
+Added: 2 dated January 18, 2018, Amendment No.
+Added: 3 dated July 2, 2018 and Amendment No.
+Added: 4 dated August 30, 2018, dated August 6, 2019 .
+Added: — — — Filed herewith
+Added: 10.12.5# Amendment No.
+Added: 3 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No.
+Added: 1 on October 18, 2017, Amendment No.
+Added: 2 dated January 18, 2018, Amendment No.
+Added: 3 dated July 2, 2018, Amendment No.
+Added: 4 dated August 30, 2018 and Amendment No.
+Added: 5 dated August 6, 2019, dated September 11, 2020 .
+Added: — — — Filed herewith
+Added: 10.12.6# Amendment No.
+Added: 6 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No.
+Added: 1 on October 18, 2017, Amendment No.
+Added: 2 dated January 18, 2018, Amendment No.
+Added: 3 dated July 2, 2018, Amendment No.
+Added: 4 dated August 30, 2018, Amendment No.
+Added: 5 dated August 6, 2019 and Amendment No.
+Added: 3 dated September 11, 2020, dated December 8, 2020.
+Added: — — — Filed herewith
+Added: 10.13+ Amended and Restated Key Executive Change in Control and Severance Plan.
+Added: 10-Q 001-38311 10.6 11/5/2020
10.14+ Executive Incentive Compensation Plan.
S-1 333-221522 10.14 11/13/2017
−Removed: 10.15+ Outside Director Compensation Policy.
−Removed: S-1 333-221522 10.15 11/13/2017
+Added: 10.15+ Amended and Restated Outside Director Compensation Policy.
+Added: — — — Filed herewith
10.16# Option and Collaboration Agreement between the Registrant and Takeda Pharmaceutical Company Limited, dated January 3, 2018.
12 unchanged sentences
10-Q/A 001-38311 10.4 12/6/2018
−Removed: 10.23 Amendment No.
−Removed: 3 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No.
−Removed: 1 on October 18, 2017 and Amendment No.
−Removed: 2 dated January 18, 2018
+Added: 10.23# Collaboration and License Agreement between registrant and Genzyme Corporation ("Sanofi"), dated October 29, 2018
+Added: 10-K 001-38311 10.25 3/12/2019
+Added: 10.24 Common Stock Purchase Agreement between the Registrant and Biogen Inc., dated August 5, 2020.
10-Q 001-38311 10.1 11/5/2020
−Removed: 10.24 Amendment No.
−Removed: 4 to Development and Manufacturing Services Agreement between the Registrant and Lonza Sales AG, dated September 6, 2017, as amended by Amendment No.
−Removed: 1 on October 18, 2017 and Amendment No.
−Removed: 2 dated January 18, 2018, and Amendment No.
−Removed: 3 dated November 8, 2018
+Added: 10.25# Provisional LRRK2 Collaboration and License Agreement between the Registrant and Biogen Inc., dated August 5, 2020.
10-Q 001-38311 10.2 11/5/2020
−Removed: 10.25# Collaboration and License Agreement between registrant and Genzyme Corporat ion ("Sanofi"), dated October 29, 2018
−Removed: 10-K 001-38311 10.25 3/12/2019
+Added: 10.26 Standstill and Stock Restriction Agreement between the Registrant and Biogen Inc., dated September 22, 2020.
+Added: 10-Q 001-38311 10.3 11/5/2020
+Added: 10.27# Definitive LRRK2 Collaboration and License Agreement between the Registrant and Biogen Inc., dated October 4, 2020.
+Added: 10-Q 001-38311 10.4 11/5/2020
+Added: 10.28# Definitive Right of First Negotiation, Option and License Agreement between the Registrant and Biogen Inc., dated October 6, 2020.
+Added: 10-Q 001-38311 10.5 11/5/2020
21.1 Subsidiaries of the Registrant
11 unchanged sentences
101 The following materials from the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, formatted in Inline XBRL:
−Removed: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations and Comprehensive Loss, (iii) Consolidated Statements of Cash Flows (iv) Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) and (v) Notes to Consolidated Financial Statements.
+Added: (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations and Comprehensive Income (Loss), (iii) Consolidated Statements of Cash Flows (iv) Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity and (v) Notes to Consolidated Financial Statements.
— — — Filed herewith
−Removed: 104 The cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2019, formatted in Inline XBRL (contained in Exhibit 101) — — — Filed herewith
+Added: 104 The cover page from the Company's Annual Report on Form 10-K for the year ended December 31, 2020, formatted in Inline XBRL (contained in Exhibit 101)
+Added: — — — Filed herewith
* The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
38 unchanged sentences
David Schenkein, M.D.
+Added: Director February 26, 2021
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.